BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim JW, Kim SY. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. Int J Mol Sci 2021;22:11322. [PMID: 34768752 DOI: 10.3390/ijms222111322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Núñez P, Quera R, Yarur AJ. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. Drugs 2023;83:299-314. [PMID: 36913180 DOI: 10.1007/s40265-023-01840-5] [Reference Citation Analysis]
2 Zurba Y, Gros B, Shehab M. Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. Biomedicines 2023;11:747. [DOI: 10.3390/biomedicines11030747] [Reference Citation Analysis]
3 Danese S, Ferrante M, Feagan BG, Peyrin-Biroulet L, Hibi T, Sandborn WJ, Schreiber S, Ritter T, Loftus EV Jr, Rogler G, Oortwijn A, Yun C, Le Brun FO, Dinoso J, Hsieh J, Vermeire S. Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. Am J Gastroenterol 2023;118:138-47. [PMID: 36113491 DOI: 10.14309/ajg.0000000000001979] [Reference Citation Analysis]
4 Brayden DJ. Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials. BioDrugs 2022. [DOI: 10.1007/s40259-022-00562-6] [Reference Citation Analysis]
5 Candelli M. Translational, Precision, and Personalized Medicine in Gastroenterology. Int J Mol Sci 2022;23. [PMID: 35897777 DOI: 10.3390/ijms23158201] [Reference Citation Analysis]
6 Herrlinger K, Stange EF. JAK-Inhibitoren: eine neue Therapieoption. Gastro-News 2022;9:38-40. [DOI: 10.1007/s15036-022-2479-1] [Reference Citation Analysis]